Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
P09960

UPID:
LKHA4_HUMAN

ALTERNATIVE NAMES:
Leukotriene A(4) hydrolase; Tripeptide aminopeptidase LTA4H

ALTERNATIVE UPACC:
P09960; B4DNQ9; F8VV40; Q6IAT6; Q9UCT7

BACKGROUND:
Leukotriene A-4 hydrolase, known for its alternative names such as Tripeptide aminopeptidase LTA4H, exhibits dual functionality. It catalyzes the formation of leukotriene B4 from LTA4, contributing to pro-inflammatory responses, and degrades the tripeptide Pro-Gly-Pro, a neutrophil attractant. This protein also aids in producing resolvin E1 and 18S-resolvin E1, crucial for anti-inflammatory and pro-resolving actions.

THERAPEUTIC SIGNIFICANCE:
Exploring the multifunctional nature of Leukotriene A-4 hydrolase offers a promising avenue for developing novel anti-inflammatory therapies, highlighting its potential in drug discovery.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.